Genotoxicity testing is an integral component of toxicity evaluation for drugs as recommended by regulatory agencies in most countries. For identifying the genotoxicity potential of compounds, Eurofins Discovery offers in vitro, non-GLP gene-tox services as recommended by regulatory agencies.
The challenge in discovering genotoxic effects during the later stages of clinical development has been higher costs and impacts on project timelines. But now, genotoxicity testing has evolved toward earlier stages of drug discovery in order to identify compounds with genotoxic liabilities early in development. And Eurofins Discovery has developed solutions.
Our Ames fluctuation assay can identify compounds that are potential mutagens, and our assay is designed for screening large numbers of compounds in a high-throughput 384-well format. For compounds that induce chromosome damage (clastogens and aneugens), Eurofins Discovery offers in vitro micronucleus screening in a 96-well plate format using automated scoring by High Content Analysis (HCA), providing both objective and consistent data.
Our gene-tox assays can be ordered individually, combined or as a selection of key in vitro toxicology services provided in our drug candidate assessment packages to provide you additional cost savings.
Perform early genotoxicity liability assessment using a rapid, cost-effective, high throughput model of multiplexed toxicity testing.
Key Areas
Ames Test
Screening compounds early in the drug discovery process is essential for the identification of compounds capable of inducing mutations.
In Vitro Micronucleus
Eurofins Discovery offers key in vitro assays for genotoxicity screening. Micronucleus formation resulting from agents that cause chromosomal damage is a hallmark of genotoxicity.
Related Resources
Related Resources
Brochures
Questions? Contact Us
You can easily get in touch with a Eurofins Discovery Expert or get help from our Customer Service team. Reach out with questions, or to discuss your specific discovery challenges.
